Systematic review and meta-analysis on certolizumab pegol for rheumatoid arthritis in adults

Article English OPEN
Bernal, J. A.; Vela, P.; Ruiz Garcia, V.; Burls, A.; Cabello, J. B.; Bort-Marti, S.;

Background\ud The appearance of tumor necrosis factor-alpha (TNFalpha) inhibitors dramatically changed the prognosis of rheumatoid arthritis. Certolizumab pegol (CZP) is a human Fab fragment of anti-TNFalpha monoclonal antibody which is approved for the treatment of rhe... View more
Share - Bookmark